Place des biomarqueurs dans la prise en charge du cancer du sein
作者： F Spyratos , E Luporsi , F André , J-P Bellocq , Y Caron
DOI: 10.1007/978-2-8178-0245-9_26
关键词:
摘要: Ce rapport dresse un etat des connaissances relatives aux biomarqueurs tissulaires uPA/PAI-1, Oncotype DX™ et MammaPrint® dans la prise en charge du cancer sein.
springer.com
sci-hub.se 参考文章(129)
K. Danø, P.A. Andreasen, J. Grøndahl-Hansen, P. Kristensen, L.S. Nielsen, L. Skriver, Plasminogen activators, tissue degradation, and cancer. Advances in Cancer Research. ,vol. 44, pp. 139- 266 ,(1985) , 10.1016/S0065-230X(08)60028-7
Maureen Cronin, Mylan Pho, Debjani Dutta, James C. Stephans, Steven Shak, Michael C. Kiefer, Jose M. Esteban, Joffre B. Baker, Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. American Journal of Pathology. ,vol. 164, pp. 35- 42 ,(2004) , 10.1016/S0002-9440(10)63093-3
A. Prechtl, N. Harbeck, C. Thomssen, C. Meisner, M. Braun, M. Untch, M. Wieland, B. Lisboa, T. Cufer, H. Graeff, K. Selbmann, M. Schmitt, F. JÄnicke, Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer. International Journal of Biological Markers. ,vol. 15, pp. 73- 78 ,(2000) , 10.1177/172460080001500114
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. Journal of the National Cancer Institute. ,vol. 93, pp. 979- 989 ,(2001) , 10.1093/JNCI/93.13.979
健二郎 青儀, What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及ぼす効果を示した論文:無作為化比較試験のメタアナリシス Mebio oncology. ,vol. 3, pp. 94- 98 ,(2006)
Early Breast Cancer Trialists' Collaborative Group, None, Polychemotherapy for early breast cancer: an overview of the randomised trials The Lancet. ,vol. 352, pp. 930- 942 ,(1998) , 10.1016/S0140-6736(98)03301-7
N. Grebenschikov, A. Geurts-Moespot, H. De Witte, J. Heuvel, R. Leake, F. Sweep, T. Benraad, A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. International Journal of Biological Markers. ,vol. 12, pp. 6- 14 ,(1997) , 10.1177/172460089701200102
Laurel A Habel, Steven Shak, Marlena K Jacobs, Angela Capra, Claire Alexander, Mylan Pho, Joffre Baker, Michael Walker, Drew Watson, James Hackett, Noelle T Blick, Deborah Greenberg, Louis Fehrenbacher, Bryan Langholz, Charles P Quesenberry, A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients Breast Cancer Research. ,vol. 8, pp. 1- 15 ,(2006) , 10.1186/BCR1412
Tamoxifen for early breast cancer: An overview of the randomised trials The Lancet. ,vol. 351, pp. 1451- 1467 ,(1998) , 10.1016/S0140-6736(97)11423-4
Matthias Kotzsch, Axel Meye, Thomaz Langerholc, Susanne Füssel, Natalie Olbricht, Sybille Albrecht, Detlev Ockert, Bernd Muehlenweg, Katrin Friedrich, Marianne Grosser, Manfred Schmitt, Gustavo Baretton, Viktor Magdolen, Thomas Luther, Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer Thrombosis and Haemostasis. ,vol. 89, pp. 705- 717 ,(2003) , 10.1055/S-0037-1613577